SEC Comment Letter for Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554) (MTNB) — Nov 14, 2016
Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554)
Date: Nov. 14, 2016 · CIK: 0001582554 · Accession: 0000000000-16-100756
AI Filing Summary & Sentiment
File numbers found in text: 333-214391
Letter
November 10 , 2016 Via E -mail Roelof Rongen Chief Executive Officer Matinas BioPharma Holdings , Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921
Re: Matinas BioPharma Holdings , Inc. Registration Statement on Form S-1 Filed November 2 , 2016 File No. 333-214391
Dear Mr. Rongen :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Johnny Gharib at (202) 551 -3170 with any questions.
Sincerely,
/s/ Joseph McCann for
Show Raw Text
November 10 , 2016 Via E -mail Roelof Rongen Chief Executive Officer Matinas BioPharma Holdings , Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 Re: Matinas BioPharma Holdings , Inc. Registration Statement on Form S-1 Filed November 2 , 2016 File No. 333-214391 Dear Mr. Rongen : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Johnny Gharib at (202) 551 -3170 with any questions. Sincerely, /s/ Joseph McCann for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Via E -mail Steven M. Skolnick, Esq. Lowenstein Sandler LLP